erbB-2 Receptor – Talk Bio

Boehringer Ingelheim breaks into oncology as FDA grants accelerated approval to Hernexeos (zongertinib) for HER2 TKD–mutated NSCLC

1 month ago talkbio0Tagged Accelerated, Approved, Beamion, Boehringer Ingelheim, competition, Confirmatory Trial, Enhertu, erbB-2 Receptor, Frequency of Responses, HER2-mutant, Hernexeos, Identifier, LUNG-1, Mutation, Non-Small Cell Lung Carcinoma, non-squamous NSCLC, Oncomine Dx Target Test, oral targeted therapy, Priority Review, Requirement, TKD, United States Food and Drug Administration, Zongertinib

Boehringer Ingelheim; Hernexeos; zongertinib; FDA approval; accelerated approval; non-squamous NSCLC; HER2 TKD mutations; Oncomine Dx Target Test; Beamion LUNG-1; objective response rate; first oral targeted therapy for HER2-mutant NSCLC; priority review; breakthrough therapy designation; confirmatory trial requirement; competition with Enhertu

Inside ASCO 2025: Big Data Drops and a Towering Campaign – Key News Highlights

3 months ago talkbio0Tagged 2025, Artificial Intelligence, ASCO, Big Data, campaigns, Cancer Research, Clinical Oncology, erbB-2 Receptor, Malignant neoplasm of breast, Malignant neoplasm of lung

ASCO 2025; cancer research; big data; campaigns; clinical oncology; artificial intelligence; HER2; lung cancer; breast cancer; therapeutic vaccines

FDA Approves Roche’s PATHWAY HER2 Test for HER2-Ultralow Metastatic Breast Cancer

7 months ago talkbio0Tagged Approved, Biochemical Pathway, Carcinoma breast stage IV, Diagnosis, Enhertu, erbB-2 Receptor, HER2-ultralow, Pet Animal, Precision Medicine, Roche (company), United States Food and Drug Administration

Roche, PATHWAY HER2 (4B5) test, FDA approval, HER2-ultralow, metastatic breast cancer, companion diagnostic, Enhertu, personalized medicine

Pfizer’s IBRANCE Demonstrates Significant Efficacy in HR+, HER2+ Metastatic Breast Cancer

9 months ago talkbio0Tagged Anti-HER2 therapy, Carcinoma breast stage IV, erbB-2 Receptor, Hormone Therapy, Ibrance, palbociclib, Phase 3, Progression-Free Survival, standard-of-care

IBRANCE (palbociclib), HR+/ HER2+ metastatic breast cancer, Phase 3 PATINA trial, Progression-free survival (PFS), Standard-of-care therapies, Anti-HER2 therapy, Endocrine therapy

Jazz Pharmaceuticals Presents Groundbreaking HER2 Biliary Tract Cancer Data Ahead of FDA Decision

1 year ago talkbio0Tagged Biliary Tract Cancer, Decision, erbB-2 Receptor, Jazz, Priority Review, United States Food and Drug Administration, Zanidatamab

Jazz Pharmaceuticals, HER2, Biliary Tract Cancer, FDA Decision, Zanidatamab, Priority Review